Drugs / epoietin zeta
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT02213653 | Apr 2013 → Nov 2014 | lymphoid system disorder, metastatic malignant neoplasm | Centre Francois Baclesse | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | epoietin zeta | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02213653 ↗ |
| Route | Subcutaneous | “Epoietin zeta at a dose of 450 IU / kg per week subcutaneously” NCT02213653 ↗ |